Skip to main content
. 2021 Dec 7;7(3):e001914. doi: 10.1136/rmdopen-2021-001914

Figure 2.

Figure 2

Neutralising ability and avidity of anti-RBD antibodies. (A) The distribution of immunoglobulin inhibitory activity measured by SPIA kit after the first dose of vaccine (T1) and after the boost (T2). Results are expressed as the percentage of inhibition of the binding of labelled ACE2 receptor to RBD coated plates. P<0.05 was considered as significant. (B) Avidity of anti-RBD IgG from vaccinated patients grouped according to treatment (GCs, anti-TNF, MTX, MMF, RTX or No Ther) and from healthy controls (NHS). For the different urea concentrations, mean binding values and SD obtained in each patient group are represented. Avidity Index is indicated in the table below (B). GCs, glucocorticoids; MMF, mycophenolate; MTX, methotrexate; NHS, normal healthy subjects; No Ther, untreated; RBD, receptor-binding domain; RTX, rituximab; SPIA, Spike Protein Inhibition Assay.